Several studies have also leveraged G-CSF priming of prophylactic DLI products, which may enhance GVL activity while mitigating GVHD through induction of immunomodulatory effects by G-CSF (72, 73, 75). This evidence concerns the gene CSF3 and graft versus host disease.